|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Thyroid carcinoma and hashimotothyroiditis显示文摘 | Intidhar Labidi S Chaabouni AM Kraiem T | 2006 | Ann Otolaryngol Chir Cervicofac2006，123，4： | 1 |
| 2 | Thyroid carcino- ma and Hashimoto thyroiditis 显示文摘 | Intidhar L S Chaabounin A M Kraiemn J | 2006 | Ann Otolaryngol Chir Cerricofac2006，123，4： | 1 |
| 3 | Thyroid carcinoma and Hashimoto thyroiditis显示文摘 | Intidhar Labidi S Chaabouni AM Kraicm T | 2006 | Ann Otolangol Chir Cervicofac2006，123，4： | 1 |
| 4 | Thyroid car- cinoma and Hashimoto thyroiditis显示文摘 | Intidhar Labidi S Chaabouni AM Kraiem T | 2006 | Ann Otolaryngol Chir Cervi- cofac2006，123，4： | 1 |
| 5 | Thyroid carcinoma and Hashimoto Thyroiditis显示文摘 | Intidhar Labidi S Chaabouni AM Kraiem J | 2006 | Ann Otolaryngol Chir Cerricofac2006，123，4： | 1 |
| 6 | Thyroid carcinoma andHashimoto,s thyroiditis 显示文摘 | Intidhar Labidi S Chaabouni AM Kraiem T et a1 | 2006 | Ann Otolaryngol Clair Cervicofac2006，123，4： | 1 |
| 7 | Thyroid carcinoma and Hashimoto thyroiditis显示文摘 | Intidhar Labidi S Chaabouni AM Kraiem T | | 0，，04： | 1 |
| 8 | Thyroid carcinoma and Hashimoto's thyroiditis 显示文摘 | Intidhar labidi S Chaabouni AM Kraiem T | 2006 | Ann Otolaryngol Clair Cervicofac2006，123，4： | 1 |
| 9 | Thyroid carcino- ma and Hashimoto thyroiditis 显示文摘 | Intidhar Labidi S Chaabouni AM Kraiem J | 2006 | Ann Otolaryngol Chir Cerricofac2006，123，4： | 1 |
| 10 | Thyroid carcino-ma and Hashimoto thyroiditis 显示文摘 | Intidhar Labidi S Chaabouni AM Kraiem T | 2006 | Ann Otolayngol Chir Cervicofac2006，123，4： | 1 |
| 11 | Thyroid carcinoma and Hashimoto thyroiditis 显示文摘 | Intidhar Labidi S Chaabouni A M Kraiem T | 2006 | Ann Otolaryngol Chir Cervicofac2006，123，4： | 1 |
| 12 | Thyroid carcinoma and Hashimoto's thyroiditis 显示文摘 | Intidhar labidi S Chaabouni AM Kraiem T | 2006 | Ann Otolaryngol Chir Cervicofac2006，123，4： | 1 |
| 13 | Thyroid carcinoma and hashimoto thyroiditis显示文摘 | Intidhar Labidi S Chaabouni AM Kraiem T | 2006 | Ann Otolaryngol Chir Cervicofac2006，123，4： | 1 |
| 14 | Thyroid carcinoma and Hashimoto thyroiditis显示文摘 | Intidhar Labidi S Chaabouni AM Kraiem T | | 0，，04： | 1 |
| 15 | Thyroid carcinoma and Hashimoto thyroiditis显示文摘 | Intidhar LS Chaabouni AM Kraiem T | 2006 | Ann Otolaryngol Chir Cervicofac2006，123，4： | 1 |
| 16 | Thyroid carcinoma and Hashimoto thyroiditis显示文摘 | Intidhar Labidi S Chaabouni AM Kraiem T | 2006 | Ann Otolaryngol Chir Cervicofac2006，123，4： | 1 |
| 17 | The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities显示文摘Ovarian cancer is the most lethal gynecologic cancer. Optimal cytoreductive surgery followed by platinum-based chemotherapy with or without bevacizumab is the conventional therapeutic strategy. Since 2016, the pharmacological treatment of epithelial ovarian cancer has significantly changed following the introduction of the poly (ADP-ribose) polymerase inhibitors (PARPi). BRCA1/2 mutations and homologous recombination deficiency (HRD) have been established as predictive biomarkers of the benefit from platinum-based chemotherapy and PARPi. While in the absence of HRD (the so-called homologous recombination proficiency, HRp), patients derive minimal benefit from PARPi, the use of the antiangiogenic agent bevacizumab in first line did not result in different efficacy according to the presence of homologous recombination repair (HRR) genes mutations. No clinical trials have currently compared PARPi and bevacizumab as maintenance therapy in the HRp population. Different strategies are under investigation to overcome primary and acquired resistance to PARPi and to increase the sensitivity of HRp tumors to these agents. These tumors are characterized by frequent amplifications of Cyclin E and MYC, resulting in high replication stress. Different agents targeting DNA replication stress, such as ATR, WEE1 and CHK1 inhibitors, are currently being explored in preclinical models and clinical trials and have shown promising preliminary signs of activity. In this review, we will summarize the available evidence on the activity of PARPi in HRp tumors and the ongoing research to develop new treatment options in this hard-to-treat population. | Teresa Zielli Intidhar Labidi-Galy Maria Del Grande Cristiana Sessa Ilaria Colombo | 2023 | Cancer Drug Resistance2023，6，3： | 0 |
| 18 | Efficacy of Essential Trace Elements Supplementation on Mineral Composition,Sperm Characteristics,Antioxidant Status,and Genotoxicity in Testis of Tebuconazole-treated Rats显示文摘Objective This research was performed to evaluate the effect of tebuconazole(TBZ)on reproductive organs of male rats and to assess the protective role of combined essential trace elements in alleviating the detrimental effect of TBZ on male reproductive function.Methods For this purpose,48 rats were exposed to 100 mg/kg TBZ,TBZ supplemented with zinc(Zn),selenium(Se),copper(Cu),and iron(Fe),TBZ+(Se+Zn);TBZ+Cu;or TBZ+Fe.The experiment was conducted for 30 consecutive days.Results TBZ caused a significant perturbation in mineral levels and reduction in reproductive organs weights,plasma testosterone level,and testicular antioxidant enzyme activities.The TBZ-treated group also showed a significant increase in sperm abnormalities(count,motility,and viability percent),plasma follicle-stimulating hormone and luteinizing hormone concentrations,lipid peroxidation,protein oxidation,and severe DNA degradation in comparison with the controls.Histopathologically,TBZ caused testis impairments.Conversely,treatment with trace elements,in combination or alone,improved the reproductive organ weights,sperm characteristics,TBZ-induced toxicity,and histopathological modifications in testis.Conclusion TBZ exerts significant harmful effects on male reproductive system.The concurrent administration of trace elements reduces testis dysfunction,fertility,and toxicity induced by TBZ. | Hajer BEN SAAD Fatma BEN ABDALLAH Intidhar BKHAIRIA Ons BOUDAWARA Moncef NASRI Ahmed HAKIM Ibtissem BEN AMARA | 2020 | Biomedical and Environmental Sciences2020，33，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员